Testing DDY391 for Sjögren's disease
Part of Bones, joints & muscles, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This study tests an experimental drug called DDY391 for people with Sjögren's disease. The goal is to see if it can reduce symptoms and improve quality of life, and to check for side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of Sjögren's disease, confirmed by a blood test for anti-Ro antibodies or a biopsy of your salivary gland.
- You cannot have another active autoimmune disease (like lupus or rheumatoid arthritis) that is the main problem.
- If you take hydroxychloroquine for Sjögren's, your dose must be 400 mg or less per day, and you must have been on the same dose for at least 4 weeks.
- You cannot have taken certain immune-suppressing drugs (like belimumab, abatacept, or cyclophosphamide) in the last 3 months, or certain cell-depleting therapies (like rituximab) in the last year.
- You must not have a current infection or a history of frequent serious infections.
- You must not have had cancer (except certain skin or cervical cancers) in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called IBI355 for people with moderate-to-severe Sjögren's disease. It aims to reduce inflammation and improve symptoms by targeting part of the immune system.
This clinical trial tests a new drug called telitacicept for people who have both Sjögren's syndrome and interstitial lung disease. The drug aims to reduce the immune system's attack on your body and may help improve lung symptoms.
This study tests an experimental medicine given by IV infusion to see if it is safe and helps reduce symptoms of lupus, sjogren's disease, or rheumatoid arthritis. It is an early-phase trial, so the main goals are checking side effects and how the drug behaves in the body, but it will also look at how well it works.
This trial tests an experimental drug called CLN-978, given as a shot under the skin, that helps your immune system target and destroy disease-causing B cells. It's for people with moderate to severe Sjögren's disease who haven't had success with other treatments.
This study tests an investigational drug called CM336 for people with active Sjögren's syndrome. It aims to see if the drug is safe and effective in reducing symptoms like joint pain and dryness when other treatments haven't worked well.
This trial tests an experimental medication called ONO-4915 for people with primary Sjögren's disease. It aims to see if the drug can reduce dryness and other symptoms.
Hear when a new Sjögren's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.